Strong fit for late-stage validation and scale-up, but the venture is pre-seed and not yet incorporated, which may be early for EIC Accelerator's TRL 6-8 focus. The €2.5M grant and €10M equity could fund clinical validation and industrialization, but the venture should first secure earlier-stage support and incorporate.